Cilastatin Ameliorates Rhabdomyolysis-induced AKI in Mice

J Am Soc Nephrol. 2021 Oct;32(10):2579-2594. doi: 10.1681/ASN.2020030263. Epub 2021 Aug 2.

Abstract

Background: Rhabdomyolysis, the destruction of skeletal muscle, is a significant cause of AKI and death in the context of natural disaster and armed conflict. Rhabdomyolysis may also initiate CKD. Development of specific pharmacologic therapy is desirable because supportive care is nearly impossible in austere environments. Myoglobin, the principal cause of rhabdomyolysis-related AKI, undergoes megalin-mediated endocytosis in proximal tubule cells, a process that specifically injures these cells.

Methods: To investigate whether megalin is protective in a mouse model of rhabdomyolysis-induced AKI, we used male C57BL/6 mice and mice (14-32 weeks old) with proximal tubule-specific deletion of megalin. We used a well-characterized rhabdomyolysis model, injection of 50% glycerol in normal saline preceded by water deprivation.

Results: Inducible proximal tubule-specific deletion of megalin was highly protective in this mouse model of rhabdomyolysis-induced AKI. The megalin knockout mice demonstrated preserved GFR, reduced proximal tubule injury (as indicated by kidney injury molecule-1), and reduced renal apoptosis 24 hours after injury. These effects were accompanied by increased urinary myoglobin clearance. Unlike littermate controls, the megalin-deficient mice also did not develop progressive GFR decline and persistent new proteinuria. Administration of the pharmacologic megalin inhibitor cilastatin to wild-type mice recapitulated the renoprotective effects of megalin deletion. This cilastatin-mediated renoprotective effect was dependent on megalin. Cilastatin administration caused selective proteinuria and inhibition of tubular myoglobin uptake similar to that caused by megalin deletion.

Conclusions: We conclude that megalin plays a critical role in rhabdomyolysis-induced AKI, and megalin interference and inhibition ameliorate rhabdomyolysis-induced AKI. Further investigation of megalin inhibition may inform translational investigation of a novel potential therapy.

Keywords: acute renal failure; chronic kidney disease; endocytosis; renal protection; rhabdomyolysis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acute Kidney Injury / drug therapy*
  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / pathology
  • Acute Kidney Injury / physiopathology
  • Animals
  • Apoptosis
  • Blood Urea Nitrogen
  • Cilastatin / pharmacology
  • Cilastatin / therapeutic use*
  • Disease Models, Animal
  • Endocytosis
  • Glomerular Filtration Rate / drug effects
  • Glomerular Filtration Rate / genetics
  • Kidney Tubules, Proximal / pathology
  • Low Density Lipoprotein Receptor-Related Protein-2 / antagonists & inhibitors
  • Low Density Lipoprotein Receptor-Related Protein-2 / genetics*
  • Male
  • Mice
  • Mice, Knockout
  • Myoglobin / blood
  • Myoglobin / metabolism*
  • Myoglobinuria / urine
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use*
  • Rhabdomyolysis / complications

Substances

  • Low Density Lipoprotein Receptor-Related Protein-2
  • Lrp2 protein, mouse
  • Myoglobin
  • Protease Inhibitors
  • Cilastatin